Axogen, Inc. (FRA:LT3)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.66B +145.7% |
| Revenue (ttm) | 191.81M +20.2% |
| Net Income | -13.37M |
| EPS | -0.29 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 67.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 31.25 |
| Previous Close | 30.67 |
| Day's Range | 31.25 - 31.25 |
| 52-Week Range | 7.85 - 31.77 |
| Beta | n/a |
| RSI | 59.90 |
| Earnings Date | Apr 28, 2026 |
About Axogen
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstr... [Read more]
Financial Performance
In 2025, Axogen's revenue was $225.21 million, an increase of 20.21% compared to the previous year's $187.34 million. Losses were -$15.70 million, 57.6% more than in 2024.
Financial numbers in USD Financial StatementsNews
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
ALACHUA, Fla. and TAMPA, Fla.
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
ALACHUA, Fla. and TAMPA, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
ALACHUA, Fla. and TAMPA, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla.
Axogen Announces Proposed Public Offering of Common Stock
ALACHUA, Fla. and TAMPA, Fla.
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
ALACHUA, Fla. and TAMPA, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
ALACHUA, Fla. and TAMPA, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical technologies for the restoration of periph...
FDA approves Axogen's nerve repair graft
The U.S. Food and Drug Administration has approved Axogen's nerve repair graft, the health regulator said on Wednesday.
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN
LOS ANGELES--(BUSINESS WIRE)--Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN.
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $AXGN--AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm.
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
ALACHUA, Fla. and TAMPA, Fla.
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025
ALACHUA, Fla. and TAMPA, Fla., July 22, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of periphera...
Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...
Axogen, Inc. Reports 2025 First Quarter Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, to...
Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025
ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today ...
Axogen, Inc. To Host Analyst & Investor Day on March 4th
ALACHUA, Fla. and TAMPA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, w...
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
ALACHUA, Fla. and TAMPA, Fla., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Craig Swandal, experienced medical device manufacturing executive, joins leadership team Craig Swandal, experienced medical device manufacturing executive, joins leadership team
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, ...
Axogen, Inc. Announces New Leadership Appointments
ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t...
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a...
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, a...
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, a...